|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | MicroRNAs are involved in the development and progression of gastric cancer显示文摘MicroRNAs (miRNAs) are recognized as an essential component of the RNA family, exerting multiple and intricate biological functions, particularly in the process of tumorigenesis, proliferation, and metastatic progression. MiRNAs are altered in gastric cancer (GC), showing activity as both tumor suppressors and oncogenes, although their true roles have not been fully understood. This review will focus upon the recent advances of miRNA studies related to the regulatory mechanisms of gastric tumor cell proliferation, apoptosis, and cell cycle. We hope to provide an in-depth insight into the mechanistic role of miRNAs in GC development and progression. In particular, we summarize the latest studies relevant to miRNAs’ impact upon the epithelial- mesenchymal transition, tumor microenvironment, and chemoresistance in GC cells. We expect to elucidate the molecular mechanisms involving miRNAs for better understanding the etiology of GC, and facilitating the development of new treatment regimens for the treatment of GC. | Xiaolin Liu Ruixia Ma Bin Yi Adam I.Riker Yaguang Xi | 2021 | Acta Pharmacologica Sinica2021，42，7： | 8 |
| 2 | Metformin and cancer immunity显示文摘The immune system plays an essential and central role in tumor cell differentiation,proliferation,angiogenesis,apoptosis,invasion,and metastasis.Over the past decade,cancer therapy has rapidly evolved from traditional approaches,such as surgery,chemotherapy,and radiotherapy,to revolutionary new treatment options with immunotherapy.This new era of cancer treatment options has now been clinically tested and applied to many forms of human malignancies,often with quite dramatic results.As we develop more effective combinations of cancer treatment,several agents have been recently investigated,putatively identified as antica ncer age nts,or imm uno stimulatory molecules.One such age nt is metformin,originally developed as a fairly standard first-line therapy for patients with type-2 diabetes mellitus(T2DM).Given the underlying mechanisms of action,researchers began to exami ne the alter native function s and possible utility of metformin,finding that the can cer risk in patie nts with T2DM was reduced.It appears that metformin,at least in part,has an antitumor effect through activation of the 5'adenosine monophosphate-activated protein kinase(AMPK)signaling pathway.Moreover,numerous studies have demonstrated that metformin interferes with key immun opathological mecha nisms that are in volved in the pathological processes or associated with maligna nt progression.Such in sights may shed light on further analyzi ng whether metformi n enhances the effectiveness of the immuno therapy and overcomes the immunotherapy resista nee in the patients.Herein,we provide a comprehe nsive review of the literature exami ning the impact of metformin upon the host immune system and cancer immunity. | Ruixia Ma Bin Yi Adam I.Riker Yaguang Xi | 2020 | Acta Pharmacologica Sinica2020，41，11： | 3 |
| 3 | Cyclin G2,a novel target of sulindac to inhibit cell cycle progression in colorectal cancer显示文摘Sulindac has shown significant clinical benefit in preventing colorectal cancer pro-gression,but its mechanism of action has not been fully elucidated.We have found that sulin-dac sulfide(SS)is able to inhibit cell cycle progression in human colorectal cancer cells,particularly through G1 arrest.To understand the underlying mechanisms of sulindac inhibitory activity,we have demonstrated that Cyclin G2 up-regulation upon SS treatment can substan-tially delay cell cycle progression by enhancing the transcriptional activity of FOXO3a in human colorectal tumor cells.MiR-182,an oncogenic microRNA known to inhibit FOXO3a gene expres-sion,is also involved in the suppressive effect of SS on cell cycle progression.This process be-gins with the down-regulation of miR-182,followed by the enhancement of FOXO3a transcriptional activity and the up-regulation of Cyclin G2.To further determine the clinical utility of this axis,we analyzed the expression of miR-182/FOXO3a/Cyclin G2 in human colo-rectal tumor samples.Our results show not only that there are significant dfferences in miR-182/FOXO3a/Cyclin G2 between tumors and normal tissues,but also that the synergetic effect of miR-182 and FOXO3a is associated with predicting tumor progression.Our study dem-onstrates a novel mechanistic axis consisting of miR-182/FOXO3a/Cyclin G2 that mediates su-lindac inhibition of cell cycle progression. | Hongyou Zhao Bin Yi Zhipin Liang Ches’Nique Phillips Hui-Yi Lin Adam I.Riker Yaguang Xi | 2021 | Genes & Diseases2021，8，3： | 2 |
| 4 | 5-氮杂-2'-脱氧胞苷体外对黑素瘤细胞系肿瘤相关抗原和免疫分子表达的影响显示文摘目的探讨5-氮杂-2'-脱氧胞苷(5-aza-2'-deoxycytidine,5-aza-CdR)对4种体外培养建系的黑素瘤细胞肿瘤相关抗原和免疫分子表达水平的影响。方法将手术切除或细针穿刺活组织检查获得的黑素瘤组织体外培养建系;应用流式细胞术检测5-aza-CdR用药后黑素瘤细胞表面人类白细胞抗原(human leukocyte antigen,HLA)-Ⅰ类、-Ⅱ类、-A2以及细胞间黏附分子1(intercellular adhesion molecule 1,ICAM-1)表达的变化;采用实时定量RT-PCR检测用药后一系列重要的肿瘤相关抗原表达的变化。结果 5-aza-CdR用药后,4种黑素瘤细胞系HLA-Ⅰ类、-Ⅱ类和-A2的表达与对照组相比无明显变化;TC12A和TC13细胞ICAM-1表达明显升高;TC12A、TC13和TC69B细胞肿瘤相关抗原黑素瘤抗原基因(MAGE)-4和NY-ESO-1的表达水平明显升高。结论 5-aza-CdR不影响黑素瘤细胞HLA的表达水平,对ICAM-1和某些黑素瘤相关肿瘤抗原的表达有明显上调作用,提示化疗药物5-aza-CdR不会阻碍抗肿瘤免疫中黑素瘤细胞的抗原呈递能力,为化疗联合免疫治疗肿瘤提供了理论前提。 | 柴丽娜 王捷熙 李伟静 刘敏霞 王璇琳 王艳 贺敏 杨超 于群 韩颖 任素萍 Adam I.Riker | 2013 | 军事医学2013，37，10： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员